Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis

Published on Mar 21, 2015in World Journal of Gastroenterology3.411
· DOI :10.3748/wjg.v21.i11.3282
Enayatullah Baki1
Estimated H-index: 1
Philipp Zwickel2
Estimated H-index: 2
+ 4 AuthorsAnnika Gauss8
Estimated H-index: 8
AIM: To evaluate the outcome of anti-tumor necrosis factor alpha (anti-TNFα) therapy in outpatients with ulcerative colitis at a tertiary referral center. METHODS: All patients with a confirmed diagnosis of ulcerative colitis undergoing therapy with infliximab and/or adalimumab at the outpatient clinic for inflammatory bowel diseases at the University Hospital Heidelberg between January 2011 and February 2014 were retrospectively enrolled. Patients with a follow-up period of less than 6 mo from start of anti-TNFα therapy were excluded. Medical records of all eligible individuals were carefully reviewed. Steroid-free clinical remission of a duration of at least 3 mo, colectomy rate, duration of anti-TNFα therapy, need for anti-TNFα dose escalation, and the occurrence of adverse events were evaluated as the main outcome parameters. RESULTS: Seventy-two patients were included (35 treated with infliximab, 17 with adalimumab, 20 with both consecutively). Median follow-up was 27 mo (range: 6-87 mo). Steroid-free clinical remission was achieved by 22.2% of the patients (median duration: 21 mo until end of follow-up; range: 3-66 mo). Patients attaining steroid-free clinical remission displayed lower hemoglobin and albumin blood levels at the start of treatment than those who did not achieve remission. The overall colectomy rate was 20.8%. Nearly 50% of the patients underwent anti-TNFα dose escalation during the follow-up period. For both the infliximab and the adalimumab treated patients, non-response to anti-TNFα therapy was the major reason for treatment discontinuation. 18.2% of the infliximab-treated patients and 13.5% of the adalimumab-treated patients had to discontinue their therapy due to adverse events. CONCLUSION: Real-life remission rates of ulcerative colitis under anti-TNFα are overall low, but some patients have a clear long-term benefit.
  • References (25)
  • Citations (9)
📖 Papers frequently viewed together
74 Citations
24 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1You Lian Zhou (Southern Medical University)H-Index: 1
#2Shan Xie (Southern Medical University)H-Index: 3
Last. Ye Chen (Southern Medical University)H-Index: 10
view all 9 authors...
Objective This study aimed to evaluate the efficacy including the patients' response rates to infliximab (IFX) therapy, relapse rates after IFX-induced clinical remission, and the safety of IFX in Chinese patients with ulcerative colitis (UC) from a single center in southern China and to identify the risk factors associated with disease relapse. Methods Medical records of Chinese UC patients who were diagnosed and received at least two infusions of IFX at Nanfang Hospital, Southern Medical Unive...
4 CitationsSource
#1Ryan W. Stidham (UM: University of Michigan)H-Index: 16
#2T. C H Lee (UM: University of Michigan)H-Index: 2
Last. Akbar K. Waljee (UM: University of Michigan)H-Index: 27
view all 10 authors...
SummaryBackground Antibodies against tumour necrosis factor-alpha (anti-TNF) are effective therapies in the treatment of ulcerative colitis (UC), but their comparative efficacy is unknown. Aim To perform a network meta-analysis comparing the efficacy of anti-TNF agents in UC. Methods After screening 506 studies, reviewers extracted information on seven studies. Traditional meta-analysis (TMA) was used to compare each anti-TNF agent to placebo. Bayesian network meta-analysis (NMA) was performed t...
90 CitationsSource
#1WilliamJSandborn (UCSD: University of California, San Diego)H-Index: 142
#2Brian G. Feagan (UWO: University of Western Ontario)H-Index: 95
Last. Paul Rutgeerts (Katholieke Universiteit Leuven)H-Index: 138
view all 14 authors...
Background & Aims Subcutaneous golimumab, a fully human monoclonal antibody to tumor necrosis factor-α (TNFα), was evaluated as maintenance therapy in TNFα antagonist-naive adults with moderate-to-severe active ulcerative colitis, despite conventional therapy, who responded to golimumab induction therapy. Methods We performed a phase 3, double-blind trial of patients who completed golimumab induction trials (Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment, e...
366 CitationsSource
#1WilliamJSandborn (UCSD: University of California, San Diego)H-Index: 142
#2Brian G. Feagan (UWO: University of Western Ontario)H-Index: 95
Last. Paul Rutgeerts (Katholieke Universiteit Leuven)H-Index: 138
view all 15 authors...
Background & Aims Little is known about the efficacy of golimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF) −α, for treatment of ulcerative colitis (UC). We evaluated subcutaneous golimumab induction therapy in TNF−α antagonist-naive patients with moderate-to-severe UC despite conventional treatment. Methods We integrated double-blind phase 2 dose-finding and phase 3 dose-confirmation trials in a study of 1064 adults with UC (Mayo score: 6−12; endoscopic subscore ≥2; 774 ...
423 CitationsSource
#1Nabeel Khan (Tulane University)H-Index: 13
#2Ali Abbas (UF: University of Florida)H-Index: 9
Last. Lydia A. L. Bazzano (Ochsner Health System)H-Index: 1
view all 5 authors...
Background & Aims There is controversy over whether the treatment of patients with ulcerative colitis (UC) with thiopurines increases their risk of lymphoma. We evaluated the risk of lymphoma (ongoing, residual, and per year of therapy) among thiopurine-treated patients with UC. Methods We obtained nationwide data from the Veterans Affairs (VA) health care system from 2001 to 2011. We performed a retrospective cohort study, analyzing data on 36,891 patients from their date of diagnosis of UC in ...
119 CitationsSource
#1Florian Bär (University of Lübeck)H-Index: 8
#2Wiebke BochmannH-Index: 1
Last. Christian SinaH-Index: 17
view all 17 authors...
Background & Aims Dysregulated energy homeostasis in the intestinal mucosa frequently is observed in patients with ulcerative colitis (UC). Intestinal tissues from these patients have reduced activity of the mitochondrial oxidative phosphorylation (OXPHOS) complex, so mitochondrial dysfunction could contribute to the pathogenesis of UC. However, little is known about the mechanisms by which OXPHOS activity could be altered. We used conplastic mice, which have identical nuclear but different mito...
34 CitationsSource
AIM: To suggest infliximab (IFX) is effective for acute severe ulcerative colitis, from real-life clinical practice. METHODS: All patients receiving IFX for the treatment of acute severe ulcerative colitis in a single centre were included. Data were extracted from clinical records in order to assess response to IFX therapy. The primary endpoint was colectomy-free survival, and secondary outcomes included glucocorticosteroid-free remission and safety, which was evaluated by recording deaths and a...
15 CitationsSource
#1Alessandro ArmuzziH-Index: 41
#2Livia BianconeH-Index: 38
Last. Claudio PapiH-Index: 31
view all 31 authors...
a b s t r a c t Background and aims: The effectiveness of adalimumab in the treatment of ulcerative colitis is under debate. Although controlled trials have shown that adalimumab is significantly better than placebo, the absolute clinical benefit is modest. We report data on the effectiveness of adalimumab in a cohort of ulcerative colitis patients treated in 22 Italian centres. Methods: All patients with active disease treated with adalimumab were retrospectively reviewed. Co- primary endpoints...
44 CitationsSource
#1WilliamJSandborn (UCSD: University of California, San Diego)H-Index: 142
#2G. Van Assche (Katholieke Universiteit Leuven)H-Index: 82
Last. Roopal ThakkarH-Index: 20
view all 10 authors...
Background & Aims Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor (TNF)-α. Its efficacy as maintenance therapy for patients with ulcerative colitis has not been studied in a controlled, double-blind trial. Methods Ulcerative colitis long-term remission and maintenance with adalimumab 2 (ULTRA 2) was a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of adalimumab in induction and maintenance of clinical remission in 494 patients with mo...
631 CitationsSource
#1Walter Reinisch (Medical University of Vienna)H-Index: 74
#2WilliamJSandborn (Mayo Clinic)H-Index: 142
Last. Roopal ThakkarH-Index: 20
view all 13 authors...
Objective The aim of this study was to assess the efficacy and safety of adalimumab (ADA), a recombinant human monoclonal antibody against tumour necrosis factor a (TNF), for the induction of clinical remission in anti-TNF nao¨ve patients with moderately to severely active ulcerative colitis. Methods This 8-week, multicentre, randomised, doubleblind, placebo-controlled study (NCT00385736), conducted at 94 centres in North America and Europe, enrolled ambulatory adult patients with Mayo score of ...
487 CitationsSource
Cited By9
Last. Andras Borsi (Janssen-Cilag)H-Index: 2
view all 5 authors...
Abstract Background Surgery plays an important role in the management of ulcerative colitis. Despite its curative intent, complications of the procedure are common and can have significant consequences to patients and care providers. We reviewed outcomes and rates of colectomy and its complications in ulcerative colitis (UC) patients in clinical practice. Materials and methods MEDLINE, MEDLINE In-Process, Embase and Cochrane databases were searched for observational studies (January 2006-May 201...
AbstractBackground: Biologics used to treat ulcerative colitis (UC) may lose their effect over time, requiring patients to undergo dose escalation or treatment switching, and systematic literature ...
#1Salvatore Bellinvia (University Hospital Southampton NHS Foundation Trust)H-Index: 1
#2J. R. Fraser Cummings (University Hospital Southampton NHS Foundation Trust)H-Index: 4
Last. Christopher J. Edwards (University Hospital Southampton NHS Foundation Trust)H-Index: 40
view all 4 authors...
Adalimumab, the first fully humanised monoclonal antibody against tumour necrosis factor alpha (TNF-α), has played a leading role in the revolution brought about by the introduction of biologics, and has received the widest range of indications among TNF-α inhibitors. Post-registration, observational and registry studies of real-life use have largely supported the outcomes seen in registrational clinical trials. With the recent loss of exclusivity for the originator medicinal product in Europe, ...
#1Silvio DaneseH-Index: 63
#2Matthieu AllezH-Index: 33
Last. S. verine Vermeire (Katholieke Universiteit Leuven)H-Index: 1
view all 14 authors...
Background: The authors aimed to conduct an extensive literature review and consensus meeting to identify unmet needs in ulcerative colitis (UC) and ways to overcome them. UC is a relapsing and remitting inflammatory bowel disease with varied, and changing, incidence rates worldwide. UC has an unpredictable disease course and is associated with a high health economic burden. During 2016 and 2017, a panel of experts was convened to identify, discuss and address areas of unmet need in UC. Methods:...
2 CitationsSource
#1Daniel J. Wong (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 6
#2Eve M. Roth (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 1
Last. Vitaliy Poylin (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 12
view all 4 authors...
1 CitationsSource
#2Wolfgang SchmidtH-Index: 1
Last. Martin Emmert (FAU: University of Erlangen-Nuremberg)H-Index: 15
view all 5 authors...
Aims We determined adalimumab utilisation and associated drug costs in patients with ulcerative colitis (UC), focusing on patients requiring dose escalation.
1 CitationsSource
Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study
13 CitationsSource
#1Erika Lehtola (HYKS: Helsinki University Central Hospital)H-Index: 1
#2Johanna Haapamäki (HYKS: Helsinki University Central Hospital)H-Index: 12
Last. Martti Färkkilä (HYKS: Helsinki University Central Hospital)H-Index: 62
view all 3 authors...
AbstractBackground: Biological medications, particularly TNF-α inhibitors, are used increasingly for active inflammatory bowel disease (IBD). Even though they are superior to many older medications in achieving remission and mucosal healing, primary nonresponse and loss of response remain significant problems, and a remarkable proportion of patients still need surgery at some point.Objective: To study the outcome of IBD patients treated with TNF-α inhibitors, either infliximab or adalimumab, wit...
3 CitationsSource
#1Christopher M. Black (MSD: Merck & Co.)H-Index: 10
#2Eric Yu (IMS Health)H-Index: 1
Last. Sumesh Kachroo (MSD: Merck & Co.)H-Index: 8
view all 4 authors...
Objective To describe the real-world use of adalimumab for maintenance treatment of ulcerative colitis (UC) and associated healthcare costs in English hospitals. Design Retrospective cohort study. Setting Analysis of NHS Hospital Episode Statistics linked with pharmacy dispensing data in English hospitals. Patients Adult UC patients receiving ≥240mg during adalimumab treatment induction, subsequently maintained on adalimumab. Outcomes Frequency and pattern of adalimumab use and dose escalation d...
10 CitationsSource
Abstract This review aimed to compile all available published data on colectomy rates following treatment using infliximab or ciclosporin in adult ulcerative colitis patients and to analyse colectomy rates, timing to colectomy and postcolectomy mortality for each treatment. We systematically reviewed the literature after 1990 reporting colectomy rates in ulcerative colitis patients treated with infliximab or ciclosporin, excluding articles on paediatric patients, patients with indeterminate coli...
4 CitationsSource